We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.
- Authors
Bischof, Johannes; Hierl, Markus; Koller, Ulrich
- Abstract
The monogenetic disease epidermolysis bullosa (EB) is characterised by the formation of extended blisters and lesions on the patient's skin upon minimal mechanical stress. Causal for this severe condition are genetic mutations in genes, leading to the functional impairment, reduction, or absence of the encoded protein within the skin's basement membrane zone connecting the epidermis to the underlying dermis. The major burden of affected families justifies the development of long-lasting and curative therapies operating at the genomic level. The landscape of causal therapies for EB is steadily expanding due to recent breakthroughs in the gene therapy field, providing promising outcomes for patients suffering from this severe disease. Currently, two gene therapeutic approaches show promise for EB. The clinically more advanced gene replacement strategy was successfully applied in severe EB forms, leading to a ground-breaking in vivo gene therapy product named beremagene geperpavec (B-VEC) recently approved from the US Food and Drug Administration (FDA). In addition, the continuous innovations in both designer nucleases and gene editing technologies enable the efficient and potentially safe repair of mutations in EB in a potentially permanent manner, inspiring researchers in the field to define and reach new milestones in the therapy of EB.
- Subjects
UNITED States. Food &; Drug Administration; EPIDERMOLYSIS bullosa; GENOME editing; GENE therapy; BASAL lamina; SKIN proteins; EPIDERMIS; SKIN
- Publication
International Journal of Molecular Sciences, 2024, Vol 25, Issue 4, p2243
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms25042243